AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M
The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases.
LocalNews
0
10
The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases.
